Sylvain G.
- Country
- France
- Department
- Hematology
Research Overview
- Phase 1 Dose Escalation Study of SGR-2921 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Evaluation of CC-95251 Monotherapy and in Combination with Antineoplastic Agents in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Evaluation of DFV890 for Safety, Tolerability, and Efficacy in Patients with Myeloid Diseases
Data & Insights
Has run more than one trial at 70 of 175 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various forms of acute myeloid leukemia (AML), with particular emphasis on refractory and relapsed cases. Their research encompasses both treatment-naive and previously treated patients.
- CD123-positive AML
- NPM1-mutated AML
- KMT2A-altered AML
Additional focus includes myelodysplastic syndrome (MDS) and its progression to AML.
Novel Therapeutic Approaches
The investigator explores innovative treatment combinations targeting refractory hematologic malignancies, particularly in patients who have failed conventional therapies.
- Venetoclax-based combinations
- Azacitidine therapy
- Targeted monotherapies
Research includes evaluation of novel agents for patients with measurable residual disease.
Treatment Optimization
Focus on developing strategies for treatment-resistant leukemia and optimizing therapeutic approaches for various patient populations.
- De-escalation strategies
- Combination therapy protocols
- First-in-human studies
Expertise in managing both adult and pediatric hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.